Year: 2026
Type: article
Abstract: Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence and mortality rates in China, thus posing huge challenges in clinical treatment. As an emerging anti-tumor therapeutic modality, monoclonal antibodies (mAbs) have undergone optimization through four developmental stages—murine, chimeric, humanized, and fully humanized—demonstrating great promise in the targeted cancer therapy background. Currently, mAbs primarily exert anti-tumor effects by targeting immune checkpoints and signaling pathways involving vascular endothelial growth factor (VEGF) and its receptors, as well as mediating mechanisms such as antibody-dependent cellular cytotoxicity (ADCC). This review systematically summarizes the classification of mAbs and their mechanisms of action in HCC treatment, aiming to provide new research perspectives for HCC immunotherapy.
Source: PubMed Central
Authors: Li Li, Wu Chuanxin, Sun Hang
Language: Chinese
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225305081